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Paucity of sensitive biomarkers to quantify transient changes in alcohol consumption level
remains a critical barrier for the development of efﬁcacious therapeutic agents to treat
alcoholism. Recently, in an 11-week, randomized, placebo-controlled, double-blind trial of
283 alcohol-dependent individuals, we demonstrated that ondansetron was efﬁcacious at
reducing the severity of drinking (measured as drinks per drinking day; DDD) in alcoholics
carrying the LL compared with the LS/SS genotype of the serotonin transporter gene,
5′-HTTLPR. Using peripheral blood samples from a cohort of 41 of these subjects, we deter-
minedwhether there was a relationship betweenmRNA expression level of the 5′-HTTLPR
genotypes (measured at weeks 0, 4, and 11) and self-reported alcohol consumption follow-
ing treatment with either ondansetron (4μg/kg twice daily; N = 19) or placebo (N = 22).
Using a mixed-effects linear regression model, we analyzed the effects of DDD and 5′-
HTTLPR genotypes on mRNA expression levels within and between the ondansetron and
placebo groups. We found a signiﬁcant three-way interaction effect of DDD, 5′-HTTLPR
genotypes, and treatment on mRNA expression levels (p = 0.0396). Among ondansetron
but not placebo recipients, therewas a signiﬁcant interaction betweenDDD and 5′-HTTLPR
genotype (p = 0.0385 and p = 0.7938, respectively). In the ondansetron group, DDD was
associated positively with mRNA levels at a greater rate of expression alteration per stan-
dard drink in those with the LL genotype (slope=+1.1698 in ln scale). We suggest that
the combination of the LL genotype and 5′-HTTLPR mRNA expression levels might be
a promising and novel biomarker to quantify drinking severity in alcoholics treated with
ondansetron.
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INTRODUCTION
Severe drinking is an important risk factor for the development of
alcohol dependence, an important cause of morbidity andmortal-
ity in the US and worldwide (Heinz et al., 2003; Bierut et al., 2010;
Paula et al., 2010). Hence, it is important to ﬁnd not only efﬁ-
cacious medicines to treat alcohol dependence but also sensitive
methods for quantifying objectively transient changes in drinking.
Several converging lines of scientiﬁc evidence have proposed
that variations in the expression of the serotonin transporter gene
in the human brain might be associated with differences in the
severity of alcohol consumption (Heinz et al., 1998; Gorwood
et al., 2000; Matsushita et al., 2001; Barr et al., 2004; Barr and
Goldman, 2006).
Indeed, dysregulation of the bio-molecular control of alcohol
consumption can predispose an individual to alcohol dependence
(Heinz et al., 2003). For instance, carriers of the homozygous high-
activity long allele (LL) of the serotonin transporter-linked poly-
morphic region (5′-HTTLPR) have been associated with reduced
intoxication and a higher risk of developing alcohol dependence
(Schuckit and Smith, 1996; Barr et al., 2003; Hinckers et al.,
2006; Buchmann et al., 2009; Laucht et al., 2009). Furthermore,
the severity of current drinking has been associated with greater
uptake of serotonin into human platelets in alcohol-dependent
individuals carrying the L allele but not in SS homozygotes (Heinz
et al., 2000; Johnson et al., 2008a). Also, it has been shown that
the expression of the LL homozygous form of the 5′-HTTLPR
genotype is inﬂuenced differentially by severe drinking (Heinz
et al., 2000; Philibert et al., 2008; Ho et al., 2011). Based on this
knowledge, we have hypothesized that the interaction between
LL genotype and alcohol consumption would be associated with
upregulation of post-synaptic receptors, and that the blockade of
upregulated 5-HT3 receptors by ondansetron would be associated
with a signiﬁcant decrease in severe drinking (Johnson, 2000).
Consistent with our hypothesis, we found, in a recent proof-
of-concept pharmacogenetic study, that ondansetron, a 5-HT3
antagonist, was signiﬁcantly more efﬁcacious in reducing drink-
ing severity in alcohol-dependent individuals carrying the LL
genotype of the 5′-HTTLPR compared with the LS or SS geno-
type (Johnson et al., 2011). Based on these previous ﬁndings,
we hypothesized further that the statistical interaction detected
between LL genotype and ondansetron treatment response might
have been mediated through the speciﬁc regulatory effects of
varying alcohol amounts on transcription rates of serotonin trans-
porter mRNA expression. As an exploratory extension of this
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hypothesis, in this proof-of-concept pilot study, we examined
whether alterations in mRNA expression of the serotonin trans-
porter were associatedwith variations in alcohol consumption and
could, therefore, be used as a novel biomarker to assess, objec-
tively, variations in alcohol consumption levels in response to
ondansetron treatment.
Currently used biomarkers to detect alcohol consumption lack
adequate speciﬁcity to distinguish moderate from heavy drinking
(Anton, 2010; Bearer et al., 2010) and do not provide quantita-
tive assessments of heavy drinking in the recent past. Another
shortcoming of the existing biomarkers of heavy drinking, such
as percentage of carbohydrate-deﬁcient transferrin and gamma-
glutamyltransferase, is that they are not particularly sensitive and
do not elevate in signiﬁcant amounts until heavy drinking has
occurred for at least a week (Litten and Fertig, 2003; Niemela,
2007). Also, the direct measurement of alcohol concentration in
blood, plasma, and breath can only be detected for 10–12 h after
heavy drinking (Jatlow and O’Malley, 2010); thus, it has limited
value inquantifyingdrinking in anoutpatient setting. Because self-
reported alcohol consumption can be unreliable (Stewart et al.,
2009), there is a need to detect biomarkers that are both sensitive
and speciﬁc. Additionally, the implementation of a novel accurate,
quantitative biomarker will enhance pharmacotherapy research
by providing a valid measure of alcohol consumption (Lee et al.,
2005; Freeman andVrana, 2010; Jatlow and O’Malley, 2010; Litten
et al., 2010).
MATERIALS AND METHODS
PARTICIPANTS
Forty-one unrelated Caucasian and Hispanic (95 and 5%, respec-
tively) alcohol-dependent subjects were included in the study. All
participants were current drinkers recruited fromCentralVirginia
as part of a larger pharmacogenetic clinical trial that tested the
efﬁcacy of ondansetron for the treatment of alcohol dependence
(Johnson et al., 2011). A detailed description of the inclusion and
exclusion criteria of the study and the characteristics of the popu-
lation has been provided elsewhere (Johnson et al., 2011). Brieﬂy,
all participants had noAxis I diagnosis other than nicotine depen-
dence according to the Diagnostic and Statistical Manual of Men-
tal Disorders, fourth edition (American Psychiatric Association,
1994),were aged 26–78 years (mean age,52.93 years), scored>8on
the Alcohol Use Disorders Identiﬁcation Test (Bohn et al., 1995),
which assessed the severity of alcohol-related problems, reported
drinking ≥21 standard drinks/week for women and ≥30 standard
drinks/week for men during the 90 days prior to enrollment, and
had a negative urine toxicologic screen for narcotics, ampheta-
mines, or sedative–hypnotics at enrollment. Enrollees presented
themselves at breath alcohol concentration levels under 0.02% at
all clinical assessment and screen visits andwere physically healthy,
not pregnant, and not using abused drugs at enrollment. All
subjects provided informed consent to participate. Demographic
characteristics are presented in Table 1.
STUDY PROCEDURES
Subjects were enrolled in an 11-week, placebo-controlled, double-
blind, randomized study, between May 13, 2006, and October 20,
2008, at the University of Virginia while they were still drinking
(i.e., without a period of abstinence). At enrollment, we collected
self-reported drinking amounts over the past 90 days, based on the
timeline follow-back method (Sobell and Sobell, 1992), and other
screening parameters, including those of physical health, breath
alcohol concentration, and additional psychosocialmeasures asso-
ciated with drinking behavior, as detailed in our previous trials
(Johnson et al., 2000, 2006, 2008b). Subjects were randomized by
serotonin transporter genotype (LL vs. LS/SS) and then into the
ondansetron and placebo groups. A detailed description of sub-
ject randomization into the ondansetron and placebo groups and
the clinical trial procedures can be found in Johnson et al. (2011).
From a subset of the total study cohort, whole blood samples were
drawn from all consenting subjects for mRNA expression studies
at the screening visit (baseline) and at weeks 4, 8, and 12 after
baseline. Daily drinking amounts for all time periods were also
collected using the timeline follow-back method at each weekly
visit to the study center.
DNA EXTRACTION AND GENOTYPING
Genomic DNA was extracted using a Gentra Puregene® kit
(QIAGEN Inc., Valencia, CA, USA). The 5′-HTTLPR L/S alle-
les were determined as described earlier (Wendland et al.,
2006; Johnson et al., 2008a) with custom-made primers
(Forward: TCCTCCGCTTTGGCGCCTCTTCC, and Reverse:
TGGGGGTTGCAGGGGAGATCCTG).
RNA EXTRACTION AND qRT-PCR
From each participant, 8ml of whole blood was drawn at screen
and then 4, 8, and 12weeks afterward. Blood collections were
performed at the same time of the day to minimize the effects
of circadian cycle variations on mRNA expression levels. Fol-
lowing blood collection, whole blood was lysed to isolate white
blood cells (WBC) using red blood cell lysis solution (QIAGEN
Inc.). Isolated WBC then were washed with phosphate-buffered
saline for further puriﬁcation, suspended in RNAlater® solu-
tion to protect the RNA from degradation (Ambion®; Applied
Biosystems, Foster City, CA, USA), and stored at −80˚C until
the total RNA was extracted with a RiboPure™Kit (Ambion®;
Applied Biosystems) according to the manufacturer’s instruc-
tions. cDNAsynthesis andquantitative real-timepolymerase chain
reaction (qRT-PCR) assays were carried out as described previ-
ously (Seneviratne et al., 2009). Each qRT-PCR experiment was
performed in triplicate. To minimize potential technical vari-
ations among samples from the four time points within sub-
jects, cDNA synthesis and qRT-PCR reactions from total RNA
samples collected at all four time points from a given subject
were performed simultaneously in a 384-well PCR plate (Applied
Biosystems). The resulting mRNA levels for the serotonin trans-
porter gene and the glyceraldehyde-3-phosphate dehydrogenase
gene (GAPDH), which was used as the housekeeping gene, were
quantiﬁed by an ABI PRISM® 7900HT (Applied Biosystems)
sequence detection system using the comparative threshold (C t)
method (Winer et al., 1999). Mean C t ratios of the serotonin
transporter to GAPDH mRNA were calculated for each time
point in all subjects at baseline and at weeks 4, 8, and 12 after
baseline for statistical analyses of genotype and treatment group
differences.
Frontiers in Psychiatry | Molecular Psychiatry March 2012 | Volume 3 | Article 23 | 2
Seneviratne and Johnson Serotonin transporter genomic biomarker and ondansetron treatment in alcoholics
STATISTICAL ANALYSES
Data quality control
All the samples were tested in triplicate with the reference gene
GAPDH, a housekeeping gene for normalization of data, to cor-
rect for variations in cDNA and/or RNA quantity. Mean C t ratios
of serotonin transporter to GAPDH gene mRNA calculated from
each triplicate for each sample were tested for variations due to
sample handling and preparation by comparing the SD with the
sample mean. All triplicates included in our analyses varied less
than 1.5 SDs from the mean. Additionally, each PCR run included
non-template controls that generated low-level signals (C t val-
ues> 40). Quality of all clinical data was assessed by a database
coordinator and a statistician.
Statistical method
The dependent variable, drinking severity,wasmeasured as weekly
drinks per drinking day (DDD), and then all DDD values for each
subject at each time point were normalized by dividing by the sub-
ject’s body mass index (BMI); the BMI-adjusted DDD is denoted
by DDD′ in Figure 1. BMI strongly correlates with blood alcohol
concentrations (Wang et al., 1992; Dettling et al., 2007); there-
fore, the adjustment of DDD with BMI is particularly important
as we utilized a peripheral WBC model for expression analyses.
As explained above, for each participant, we quantiﬁed serotonin
transporter mRNA expression levels at four time points (base-
line and weeks 4, 8, and 12); as these measures were collected
from the same participant, they were considered as repeated mea-
sures that reﬂected alterations throughout the treatment period.
Therefore, to analyze how serotonin transporter mRNA expres-
sion levels vary across the treatment period (baseline and weeks
4, 8, and 12) in response to varying drinking amounts (adjusted
by BMI; DDD′), we employed a repeated-measures, mixed-effects
linear regressionmodel. The ﬁttedmodel included baselineDDD′,
age, gender, and self-deﬁned ethnicity as covariates. Prior to sta-
tistical analyses, all ratios of serotonin transporter to GAPDH
mRNA were transformed to natural logarithms. The effects of
DDD′ on repeated measures of mRNA expression levels were
assessed ﬁrst for the total cohort and then for each of the four
“genotype× treatment” groups separately – i.e., LL genotype car-
riers treated with ondansetron, LL carriers treated with placebo,
LS/SS carriers treatedwith ondansetron, and LS/SS carriers treated
with placebo. This approach allowed us to examine both genotype
and ondansetron treatment effects on trends of serotonin trans-
portermRNAexpression alterations in response to varying alcohol
doses. Statistical signiﬁcance for the associations between DDD′
and serotonin transporter mRNA expression levels were assessed
by the p-values derived from the repeated-measures,mixed-effects
linear regression model.
RESULTS
At baseline, DDD′ and serotonin transporter mRNA expres-
sion levels did not differ signiﬁcantly among the four geno-
type× treatment groups (LL-ondansetron, LS/SS-ondansetron,
LL-placebo, and LS/SS-placebo). Baseline demographic and bio-
logical characteristics of the cohort are given in Table 1.
From Table 2, it can be seen that the analyses of the total
cohort showed a signiﬁcant three-way interactive effect of DDD′,
5′-HTTLPR genotype, and treatment on predicting the mRNA
expression levels (N = 41, F = 4.64, p = 0.0396). Interestingly,
when the two treatment groups were analyzed separately, the
Table 1 | Baseline demographic and biological characteristics*.
Outcome Ondansetron (N =19) Placebo (N =22)
LL (N =7) LS/SS (N =12) LL (N =7) LS/SS (N =15)
Age in years 54.143 (8.764) 52.083 (16.572) 49.571 (14.547) 54.600 (12.988)
Sex, no. (%)
Male 3 (43) 9 (75) 4 (57) 13 (93)
Female 4 (57) 3 (25) 3 (43) 1 (7)
Race/ethnicity, no. (%)
White 7 (100) 12 (100) 7 (100) 13 (87)
Hispanic – – – 2 (13)
Self-reported drinks/drinking day† 0.540 (0.183) 0.625 (0.438) 0.535 (0.558) 0.506 (0.864)
Mean baseline expression 1.550 (0.593) 1.454 (0.605) 1.410 (0.724) 1.660 (0.514)
Breath alcohol concentration, % 0.000 0.000 0.000 0.003 (0.010)
Age of alcoholism onset in years 43.600 (16.906) 38.000 (17.311) 30.714 (10.610) 36.583 (19.528)
Social class, no. (%)‡
1–3 4 8 5 9
4–6 2 4 2 4
7–9 1 – – 1
Body mass index, kg/m2 17.122 (3.594) 26.405 (12.858) 22.997 (12.700) 17.841 (4.685)
*Values are expressed as mean (SD) unless otherwise indicated. All values were collected at the screening visit.
† Reﬂects mean values during the 90-day period preceding the screening visit.
‡Deﬁned by Hollingshead and Redlich (1958).
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FIGURE 1 | Association between drinking severity and serotonin
transporter (SERT) mRNA expression levels during 11weeks of
treatment. SLC6A4 gene expression changes in human white blood cells
with the amount of severe drinking (drinks per drinking day; DDD′) and
genotypic variation of the serotonin transporter-linked polymorphic region in
subjects treated with (A) ondansetron (N =19) and (B) placebo (N =22). The
closed symbols represent covariate adjusted individual expression levels, and
the dark lines represent expression level changes associated with drinking
severity in LL subjects; the open symbols and light lines represent the
corresponding changes in LS/SS subjects. The intercepts and slopes for
expression levels in the LL and LS/SS ondansetron groups were estimated
from a linear mixed-effects model: y =−0.4566+1.1698× x and
y =0.3524−0.4385× x, respectively. The corresponding estimates for the LL
and LS/SS placebo groups were y =0.2417−0.3150× x and
y =0.2919−0.3363× x, respectively. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase gene.
Table 2 | Effects of variables included in the mixed-effects linear regression model on serotonin mRNA expression levels.
Effect Estimate SE df t -Value p-Value
Intercept 1.2923 0.3885 24 3.33 0.0028
5′-HTTLPR genotype −0.0502 0.2843 29.8 −0.18 0.8611
Treatment 0.0605 0.1895 23.4 0.32 0.7521
5′-HTTLPR genotype× treatment −0.7588 0.4014 35.2 −1.89 0.0669
DDD′ −0.3363 0.3182 11.9 −1.06 0.3115
5′-HTTLPR genotype×DDD′ 0.0213 0.4950 24 0.04 0.9660
Treatment×DDD′ −0.1022 0.3510 15.1 −0.29 0.7750
5′-HTTLPR genotype× treatment×DDD′ 1.587 0.7370 29.4 2.15 0.0396
Study week −0.0317 0.0069 10 −4.61 0.0010
Age −0.0035 0.0046 19.7 −0.77 0.4495
Gender 0.0279 0.1674 23.3 0.17 0.8695
Baseline serotonin transporter mRNA expression −0.3783 0.1077 20.3 −3.51 0.0022
DDD ′ =drinking severity expressed as drinks per drinking day corrected by body mass index.
interaction between DDD′ and serotonin transporter genotype
was signiﬁcant only within the ondansetron treatment group, but
not within the placebo group (N = 19, F = 4.96, p = 0.0385, and
N = 22, F = 0.07, p = 0.7938, respectively). The mRNA expres-
sion levels in all subjects who received ondansetron and placebo
are shown in Figures 1A,B, respectively; the symbols in the
two panels represent mRNA expression levels at each time point
(weeks 4, 8, and 12) for all the individuals included in the “geno-
type× treatment” groups. As described in the Figure 1 legend,
we then estimated slopes for the associations between DDD′ and
mRNA expression throughout the entire study period (baseline to
week 12) by utilizing a repeated-measures,mixed-effectsmodel.As
illustrated in Figure 1, subjects carrying the LL genotype whowere
treated with ondansetron showed a trend toward having decreased
serotonin transporter mRNA expression levels with decreasing
drinking levels (slope=+1.1698) during the 11-week treatment
period. In contrast, those with the LS or SS genotype who were
treated with ondansetron showed a trend toward having increased
serotonin transporter mRNA expression levels with decreasing
drinking levels (slope=−0.4385) during the 11-week treatment
period. Serotonin transporter mRNA expression levels in both
LL and LS/SS subjects who were treated with placebo showed a
trend toward increased expression with decreasing drinking levels
(slope=−0.3150 for LL, slope=−0.3363 for LS/SS).
DISCUSSION
The primary goal of this study was to examine for the possibility
of utilizing the combination of mRNA expression levels and the
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LL genotype of the serotonin transporter gene as a genomic bio-
marker to assess, objectively and quantitatively, changes in drink-
ing severity in response to ondansetron treatment. During the
11-week treatment period, serotonin transporter mRNA expres-
sion levels within LL subjects treated with ondansetron decreased
at a rate of ln(1.164) with decreasing drinking severity, implying
approximately a threefold reduction of serotonin transporter
mRNA expression levels for an increase in one standard drink
per drinking day.
Interestingly, the rates of serotonin transporter mRNA alter-
ations were more than 50% less in the remaining three “geno-
type× treatment” groups, compared with serotonin transporter
mRNA expression level alterations per unit of standard drink per
drinking day in alcohol-dependent individuals with the LL geno-
type who were treated with ondansetron. Furthermore, unlike in
the LL-ondansetron group, in all three of these groups (S-carriers
treated with ondansetron and LL and S-carrier subjects who
received a placebo), associations between serotonin transporter
mRNA expression and drinking severity showed negative trends.
Additionally, the negative trends within the placebo treatment
group did not differ signiﬁcantly between the two serotonin trans-
porter genotype groups. One possibility for this observation is the
lack of signiﬁcant drinking severity reductions in these groups,
or perhaps an unknown direct regulatory effect of ondansetron
on serotonin transporter gene expression. To our knowledge, the
exact mechanism of serotonin transporter regulation under the
condition of severe drinking is not yet characterized. Neverthe-
less, there is growing evidence that serotonin transporter gene
expression differences among alcohol-dependent individuals with
the LL genotype, compared with S-carriers, may be regulated by
epigeneticmechanisms, such asmethylation in alcohol-dependent
individuals (Philibert et al., 2007, 2008) and transcription factor
binding in subjects with obsessive–compulsive disorder (Hu et al.,
2006).
There are at least three promising aspects to quantifying sero-
tonin transporter mRNA levels within LL genotype carriers as a
serotonin transporter genomic biomarker for predicting drink-
ing severity. First, unlike any of the currently existing biomarkers
of alcohol consumption, the serotonin transporter genomic bio-
marker targets a pathophysiological mechanism in the brain asso-
ciated with heavy drinking (Johnson, 2005; Johnson et al., 2011).
For this reason, in addition to serving as a marker for treatment
outcome, it alsomay be a surrogate endpoint marker for the sever-
ity of the disease itself. Second, because the marker is tested in
populations carrying a speciﬁc genetic variant (the LL genotype),
the individual variability on serotonin transporter mRNA expres-
sion levels will be less. Third, the serotonin transporter genomic
biomarker can be tested in research or clinical facilities with access
to a genetic laboratory.
The main limitation of our study is the small sample size in
each of the genotype× treatment groups. We did, however, have
a minimum of seven subjects in each group and, therefore, six
degrees of freedom (df), which is greater than the minimum of
ﬁve df recommended by Churchill (2002) for each group in gene
expression analyses with the microarray technique. Nevertheless,
additional studies with a larger sample size will be needed to
replicate our ﬁndings. Another notable limitation was that the
self-reported drinking data could not be veriﬁed independently.
Thus, the development of serotonin transporter mRNA levels as
a potential novel biomarker would require studies that charac-
terize directly its sensitivity and speciﬁcity, in both healthy and
alcohol-dependent individuals, under conditions where known
amounts of alcohol are administered under either a ﬁxed or vary-
ing schedule. Another notable drawback of our study is the lack
of consensus among researchers on the association between 5′-
HTTLPR genotypes and alcoholism.Although an association with
alcoholism would be a preferable aspect of a genetic marker for
drinking severity, it should also be noted that the pharmacological
response to alcohol may involve genes or genetic variants within
those genes that are different from the genetic factors governing
disease susceptibility. Toour knowledge, there are no genome-wide
association studies that have examined genetic associations with
drinking severity. In this light, based on our previous biochem-
ical and molecular studies that led us to develop the hypothesis
for the present study, we believe that the 5′-HTTLPR genotypes
are a reasonable genetic marker to predict serotonin transporter
expression level alterations in response to severe drinking. Fur-
thermore, if successfully validated, our biomarker development
strategy may provide a model for screening and validation of
other potential genomic markers for drinking severity in the
future.
In sum, our ﬁndings provide the preliminary evidence for the
possibility of utilizing the combination of the serotonin trans-
porter LL genotype and mRNA levels as a novel biomarker to
assess, quantitatively and objectively, alcohol consumption levels
in alcohol-dependent individuals treated with ondansetron.
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